Q32 Bio (QTTB) Other Non-Current Assets (2017 - 2026)
Q32 Bio (QTTB) recorded quarterly Other Non-Current Assets of $647000.0 in Q1 2026, little changed quarter-over-quarter from $647000.0 in Q4 2025, and little changed on a YoY basis from $647000.0 in Q1 2025.
Q32 Bio (QTTB) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Q32 Bio's Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $647000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $647000.0; the TTM figure through Mar 2026 stood at $647000.0 (changed 0.0% YoY), while the FY2025 annual figure was $647000.0, up 457.76% from the prior year.
- Other Non-Current Assets was $647000.0 for Q1 2026 at Q32 Bio, roughly flat from $647000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.6 million in Q1 2023 to a low of $23000.0 in Q4 2023.
- Historically, Other Non-Current Assets has averaged $1.6 million across 5 years, with a median of $647000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets surged 1946.01% in 2023, then slumped 99.29% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $276000.0 in 2022, then slumped by 91.67% to $23000.0 in 2023, then jumped by 404.35% to $116000.0 in 2024, then jumped by 457.76% to $647000.0 in 2025, then changed by 0.0% to $647000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $647000.0 (Q1 2026), $647000.0 (Q4 2025), and $647000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | 647,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 647,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Jun 30, 2025 | 647,000.00 |
| Mar 31, 2025 | 647,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 647,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Dec 31, 2023 | 23,000.00 |
| Sep 30, 2023 | 5.65 Mn |
| Jun 30, 2023 | 5.65 Mn |
| Mar 31, 2023 | 5.65 Mn |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 1.95 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Sep 30, 2020 | 1.27 Mn |
| Jun 30, 2020 | 1.27 Mn |